Agios Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs Our mature and unique understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together
Pipeline - Agios Agios has a proven track record of leveraging our expertise in cellular metabolism to develop new therapies and bring innovative medicines to patients in need Building on our core capabilities, we are advancing a robust pipeline focused on rare diseases
About Us - Agios At Agios, building bonds and cultivating relationships are at the heart of our ability to create life-changing therapies for people with rare diseases We are a biopharmaceutical company that believes connections unlock potential
Leadership - Agios At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments for patients with rare diseases more collaborative, creative and productive
Investors Overview – Agios Pharmaceuticals, Inc. The Investor Relations website contains information about Agios Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
Our Medicine - Agios At Agios, people living with rare diseases are at the center of everything we do and every decision we make Their needs, concerns, input and collaboration are essential to fulfilling our mission: to make a meaningful difference in patients’ lives and fundamentally change the way rare diseases are treated
News - Agios Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases Read More
Medical - Agios This site contains educational and scientific information relating to Agios investigational and approved medicines
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and . . . Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases In the U S , Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating